Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 7/20 | 0.38 |
| ▸ | BPTF | Q12830 | 2/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13326607 | 0.75 | CHRM2 (0.44) | TSHRPRKCIHRH4HRH3HRH2 | |
| SCHEMBL974801 | 0.75 | CHRM2 (0.44) | TSHRPRKCIHRH4HRH3HRH2 | |
| SCHEMBL13326604 | 0.75 | CHRM2 (0.44) | TSHRPRKCIHRH4HRH3HRH2 | |
| SCHEMBL30098909 | 0.73 | SLC6A2 (0.43) | CYP1A2TSHRPRKCIHRH4HRH3 | |
| SCHEMBL13326581 | 0.71 | PRKCI (0.44) | PRKCI | |
| SCHEMBL26775804 | 0.71 | PRKCI (0.44) | PRKCI | |
| SCHEMBL13326564 | 0.70 | HRH4 (0.41) | PRKCIBPTFHRH4HRH3HRH2 | |
| SCHEMBL31194807 | 0.68 | PRKCI (0.37) | PRKCICHEK2CHEK1 | |
| SCHEMBL23703360 | 0.68 | IDH2 (0.45) | PRKCICHEK2CHEK1KCNH2 | |
| SCHEMBL23703358 | 0.68 | IDH2 (0.45) | PRKCICHEK2CHEK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713965-B2 | 7-substituted 3-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials | VETOQUINOL SA (FR) | 2010-05-11 | — | — | US | disclosed |
| US-7713965-B2 | 7-substituted 3-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials | VETOQUINOL SA (FR) | 2010-05-11 | — | — | US | disclosed |
| US-20090221565-A1 | NOVEL 7-SUBSTITUTED 3-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS | VETOQUINOL SA (FR) | 2009-09-03 | — | — | US | disclosed |
| US-20090221565-A1 | NOVEL 7-SUBSTITUTED 3-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS | VETOQUINOL SA (FR) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221565-A1 | NOVEL 7-SUBSTITUTED 3-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS | CBR3, CBR1, TECR | CYP1A2 948/4885TSHR 151/4885PRKCI 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.